Archives
MG-262 (Z-Leu-Leu-Leu-B(OH)2): Reversible, Cell-Permeable...
MG-262 (Z-Leu-Leu-Leu-B(OH)2): Reversible, Cell-Permeable Proteasome Inhibitor for Precise Proteostasis Studies
Executive Summary: MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a reversible, cell-permeable proteasome inhibitor with an IC50 of 122 nM against chymotryptic activity, facilitating nanomolar-level control of proteasome function in vitro and in vivo (APExBIO). It induces cell cycle arrest and apoptosis by accumulating ubiquitinated proteins and activating caspase-3 and PARP pathways (source). MG-262 demonstrates robust inhibition of proteasome activity in multiple organs after intravenous administration in animal models (Nature Metabolism). The compound is highly soluble in DMSO (≥24.57 mg/mL) and ethanol (≥96.4 mg/mL), but insoluble in water. For optimal performance, solutions should be freshly prepared, and storage at -20°C is required to maintain stability (product data).
Biological Rationale
The ubiquitin-proteasome system (UPS) is responsible for regulated protein degradation in eukaryotic cells (Nature Metabolism). Dysregulation of UPS contributes to pathologies such as cancer, neurodegeneration, and muscle wasting. Proteasome inhibitors, including MG-262, enable precise modulation of protein turnover, supporting studies in apoptosis, cell cycle, and proteostasis (Unlocking New Horizons in Proteostasis). MG-262's boronic acid moiety confers high affinity and selectivity for the chymotryptic active site of the proteasome. This selectivity is critical for distinguishing proteasome-related pathways from autophagic or lysosomal processes, which also contribute to protein homeostasis—but via distinct mechanisms (Nature Metabolism).
Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)
MG-262 is a reversible, competitive inhibitor of the 20S proteasome. It selectively targets the chymotrypsin-like activity by covalently and reversibly binding to the catalytic N-terminal threonine of the β5 subunit. This boronic peptide acid structure enables cell permeability, allowing rapid access to intracellular proteasomes (APExBIO). Upon binding, MG-262 blocks proteolytic degradation of ubiquitinated proteins, resulting in their cellular accumulation. This triggers cascade events such as loss of mitochondrial membrane potential, caspase-3 activation, and poly(ADP-ribose) polymerase (PARP) cleavage—key features of apoptosis (source). MG-262 also modulates signaling networks, including c-Jun phosphorylation and MAP kinase phosphatase-1 expression, further influencing cell cycle arrest and programmed cell death.
Evidence & Benchmarks
- MG-262 inhibits chymotryptic activity of the proteasome with an IC50 of 122 nM in cell-based assays (APExBIO).
- In vitro, MG-262 induces dose-dependent inhibition of osteoclast differentiation and suppresses proliferation/collagen expression in nasal mucosa fibroblasts (source).
- Intravenous administration in rodent models achieves significant proteasome inhibition in heart, lung, skeletal muscle, and liver tissues (Nature Metabolism).
- MG-262 triggers mitochondrial membrane potential loss, caspase-3 activation, PARP cleavage, and cell cycle arrest in multiple cell lines (Reliable Proteasome Inhibitor).
- Highly soluble in DMSO (≥24.57 mg/mL) and ethanol (≥96.4 mg/mL), facilitating preparation of concentrated stock solutions (APExBIO).
- Stable as a solid at -20°C; solutions should be freshly prepared for experimental use (APExBIO).
For further discussion of laboratory implementation, see MG-262: Scenario-Driven Solutions, which focuses on troubleshooting and protocol optimization. This current article extends that discussion by providing molecular benchmarks and clarifying the compound's selectivity across cell types.
For detailed mechanistic insights, MG-262: Unraveling Proteasome Inhibition explores MG-262's unique role in autophagy and muscle aging research, which is complemented here by a more granular focus on apoptosis and cell cycle control.
Applications, Limits & Misconceptions
MG-262 is broadly used in research on:
- Apoptosis induction and cell cycle arrest: Enables controlled activation of caspase pathways and study of cell fate decisions.
- Ubiquitin-proteasome system (UPS) dynamics: Used to dissect proteasome-mediated protein degradation and its interplay with autophagy in muscle, cancer, and neurodegenerative models (Nature Metabolism).
- Inhibition of osteoclast differentiation: Demonstrates dose-dependent suppression of bone-resorbing cell formation in vitro (source).
- Fibroblast proliferation and collagen expression studies: Reduces proliferation in nasal mucosa and polyp fibroblasts, relevant for fibrosis models.
- In vivo proteasome inhibition: Yields multi-organ inhibition after systemic administration in rodent models, supporting translational research (Nature Metabolism).
For a strategic overview of MG-262 in proteostasis and translational modeling, see Unlocking New Horizons in Proteostasis, which this article updates by including new in vivo benchmarks and solubility data.
Common Pitfalls or Misconceptions
- MG-262 is not effective in water: The compound is insoluble in aqueous buffers; DMSO or ethanol must be used as solvents (APExBIO).
- Long-term storage in solution reduces potency: MG-262 degrades in solution; always prepare fresh working aliquots (APExBIO).
- Not a pan-protease inhibitor: MG-262 selectively targets the proteasome's chymotryptic activity, not other protease classes.
- Does not directly induce autophagy: While proteasome inhibition affects proteostasis, MG-262's primary action is not autophagy activation (Nature Metabolism).
- Cell permeability is context-dependent: Permeability may vary with cell type and assay conditions—empirical validation is recommended.
Workflow Integration & Parameters
For research protocols, dissolve MG-262 at ≥24.57 mg/mL in DMSO or ≥96.4 mg/mL in ethanol. Prepare working dilutions immediately prior to use; stock solutions can be stored at -20°C for several months (APExBIO). Typical experimental concentrations range from 10 nM to 1 μM, depending on cell type, endpoint assay, and desired proteasome inhibition. The compound is suitable for apoptosis, cell cycle, and proteasome inhibition assays across cancer, inflammatory, and neurodegenerative models. For reproducibility, include vehicle controls and validate inhibition using ubiquitinated protein accumulation or fluorogenic substrate assays.
APExBIO supplies MG-262 under SKU A8179 with validated batch records and solubility data. For scenario-driven workflow troubleshooting, see MG-262: Scenario-Driven Solutions, which this article augments by highlighting stability and selectivity benchmarks.
Conclusion & Outlook
MG-262 (Z-Leu-Leu-Leu-B(OH)2) remains a reference-standard, reversible proteasome inhibitor for dissecting UPS function, apoptosis, and cell cycle regulation in research settings. Its high selectivity, cell permeability, and robust solubility parameters enable reproducible experimental outcomes when integrated with proper storage and handling. Ongoing advances in proteostasis research, including the interplay between proteasome inhibition and autophagy, position MG-262 as a critical tool for both foundational and translational studies. For product specifications and ordering, visit the MG-262 product page at APExBIO.